(Q37372203)

20 August 2017

1 reference

title

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk (English)

1 reference

20 August 2017

0 references

1 reference

P J Barrett-Lee

1 reference

20 August 2017

J M Dixon

1 reference

20 August 2017

C Farrell

1 reference

20 August 2017

A Jones

1 reference

20 August 2017

R Leonard

1 reference

20 August 2017

N Murray

1 reference

20 August 2017

C Palmieri

1 reference

20 August 2017

C J Plummer

1 reference

20 August 2017

A Stanley

1 reference

20 August 2017

M W Verrill

1 reference

20 August 2017

language of work or name

1 reference

19 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

page(s)

816-827

1 reference

Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Early breast cancer therapy and cardiovascular injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Cardiotoxicity of Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Monitoring of anthracycline-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Pathophysiology and diagnosis of cancer drug induced cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Anthracycline cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Detection and monitoring of cardiotoxicity-what does modern cardiology offer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Interference of breast implants with echocardiographic image acquisition and interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction. Diagnosis of adriamycin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN728

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN728

1 reference

20 August 2017

1 reference